IFS Group LLC Acquires New Holdings in Eli Lilly and Company $LLY

Posted by Stanley Muller on Jul 30th, 2026

Eli Lilly and Company logo IFS Group LLC bought a new position in Eli Lilly and Company (NYSE:LLY – Free Report) during the 1st quarter, Holdings Channel reports. The institutional investor bought 517 shares of the company’s stock, valued at approximately $476,000.

Other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of Eli Lilly and Company by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock worth $88,087,193,000 after buying an additional 1,006,885 shares during the last quarter. State Street Corp increased its position in Eli Lilly and Company by 1.8% during the fourth quarter. State Street Corp now owns 35,361,916 shares of the company’s stock valued at $38,002,744,000 after acquiring an additional 635,358 shares during the last quarter. Morgan Stanley lifted its holdings in Eli Lilly and Company by 2.7% in the fourth quarter. Morgan Stanley now owns 15,593,019 shares of the company’s stock valued at $16,757,510,000 after acquiring an additional 407,166 shares during the period. Capital World Investors boosted its position in Eli Lilly and Company by 0.4% in the fourth quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock worth $16,154,619,000 after purchasing an additional 61,851 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in Eli Lilly and Company by 10.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company’s stock worth $16,024,022,000 after purchasing an additional 1,432,069 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Lilly’s pipeline beyond its GLP-1 weight-loss franchise—including oncology and other newer medicines—is expected to support future growth and diversify the business. Analysts also point to several potentially important programs moving through development. Lilly pipeline article
Positive Sentiment: The company’s $2.8 billion acquisition of AtaiBeckley expands its presence in emerging psychedelic-based mental-health treatments, signaling that Lilly is investing beyond its current GLP-1 leadership. Lilly AtaiBeckley acquisition article
Positive Sentiment: Expansion of research and development activity in China, along with plans for a new Lehigh Valley manufacturing plant, could strengthen Lilly’s global research and production capacity. Lilly China R&D article
Neutral Sentiment: Lilly is one of the market’s most closely watched companies in next week’s earnings slate. The report may be a near-term catalyst, particularly as investors assess demand for its GLP-1 medicines and progress in its broader portfolio. Week ahead earnings preview
Negative Sentiment: Pre-earnings estimates are mixed. Zacks says Lilly may lack the indicators typically associated with an earnings beat, while Erste Group reduced its FY2026 EPS forecast to $35.34 from $36.33. That caution may be weighing on the stock ahead of results. Lilly earnings expectations

Eli Lilly and Company Trading Down 0.8%

Shares of Eli Lilly and Company stock opened at $1,210.32 on Thursday. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The firm has a market cap of $1.14 trillion, a price-to-earnings ratio of 43.00, a PEG ratio of 1.52 and a beta of 0.51. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,249.45. The business has a 50-day moving average price of $1,148.72 and a 200-day moving average price of $1,042.77.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm’s revenue was up 55.5% on a year-over-year basis. During the same period in the prior year, the company earned $3.34 earnings per share. Equities research analysts anticipate that Eli Lilly and Company will post 34.91 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is 24.58%.

Analysts Set New Price Targets

LLY has been the subject of several research reports. Wolfe Research reaffirmed an “outperform” rating and set a $1,350.00 price target on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Jefferies Financial Group raised their price objective on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a report on Tuesday, June 9th. Wall Street Zen lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 18th. UBS Group upped their target price on shares of Eli Lilly and Company from $1,250.00 to $1,425.00 and gave the company a “buy” rating in a report on Monday, July 13th. Finally, Cantor Fitzgerald increased their price target on shares of Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the stock an “overweight” rating in a research report on Monday, July 6th. Two analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,283.64.

Get Our Latest Stock Report on LLY

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.